Ocular Therapeutix, Inc.
Ocular Therapeutix develops therapies for eye diseases using bioresorbable hydrogel technology. Products include DEXTENZA for post-surgical ocular inflammation and pain. AXPAXLI is being developed for wet age-related macular degeneration and retinal diseases. PAXTRAVA treats open-angle glaucoma or ocular hypertension. OTX-CSI treats dry eye disease, while OTX-DED is in phase 2 trials for dry eye symptoms. The company collaborates with Regeneron Pharmaceuticals on retinal disease treatments and AffaMed Therapeutics on DEXTENZA and OTX-TIC. Ocular Therapeutix was incorporated in 2006 and is headquartered in Massachusetts.
Overview
Strengths
- Pricing power: gross margin has held between 87% and 91% over the last 6 years (latest 87.3%).
- Consistent growth: revenue has compounded at 24.4% a year over 5 years, rising in 4 of them.
- Paying down debt: long-term debt fell by 6.1 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 9.3% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 40.9% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
Key Financial Data